Signalling inhibition by ponatinib disrupts productive alternative lengthening of telomeres (ALT)

Alternative lengthening of telomeres (ALT) supports telomere maintenance in 10–15% of cancers, thus representing a compelling target for therapy. By performing anti-cancer compound library screen on isogenic cell lines and using extrachromosomal telomeric C-circles, as a bona fide marker of ALT acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kusuma, Frances Karla, Prabhu, Aishvaryaa, Tieo, Galen, Ahmed, Syed Moiz, Dakle, Pushkar, Yong, Wai Khang, Pathak, Elina, Madan, Vikas, Jiang, Yan Yi, Tam, Wai Leong, Kappei, Dennis, Dröge, Peter, Koeffler, H. Phillip, Jeitany, Maya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079688/
https://www.ncbi.nlm.nih.gov/pubmed/37024489
http://dx.doi.org/10.1038/s41467-023-37633-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10079688/
https://www.ncbi.nlm.nih.gov/pubmed/37024489
http://dx.doi.org/10.1038/s41467-023-37633-3

Ejemplares similares